CHM.CN Stock Surges 900% in April 2026 on Waverunner Capital Rebranding

CHM.CN stock has delivered a stunning 900% gain in recent trading, reaching C$0.05 per share on the CNQ exchange. Waverunner Capital Inc., formerly known as Chemistree Technology Inc., completed its strategic rebranding in June 2024 to focus on venture capital investments. The company now specializes in early-stage funding, PIPEs, bridge financing, and growth capital across Europe and North America. Based in North Vancouver, Canada, Waverunner targets equity investments between C$500k and C$1 million with enterprise values of C$2 million to C$5 million. This dramatic price movement reflects market interest in the company’s new venture capital direction and diversified portfolio spanning healthcare, renewable energy, and biotechnology sectors.

CHM.CN Stock Performance and Market Metrics

CHM.CN stock has experienced extraordinary volatility recently. The stock climbed from a previous close of C$0.005 to C$0.05, representing the 900% surge that captured market attention. The company’s market capitalization stands at approximately C$37.2 million with 744.2 million shares outstanding.

The 50-day moving average sits at C$0.0424, while the 200-day average is C$0.0481, indicating the stock is trading above both key technical levels. Year-to-date performance shows significant volatility, with the stock trading between a 52-week low of C$0.05 and a 52-week high of C$0.10. Average daily volume of 28,908 shares suggests moderate liquidity for this micro-cap venture capital firm on the CNQ exchange.

Waverunner Capital’s Investment Strategy and Portfolio

Waverunner Capital Inc. operates as a diversified venture capital firm with a focus on early-stage and growth-stage investments. The company manages investments through its own balance sheet and personal capital, targeting opportunities in Europe and North America with specific enterprise value parameters.

The firm’s portfolio spans multiple high-growth sectors including renewable energy (wind and solar), plant-based wellness, consumer-targeted biotechnology, and natural resources. CEO Karl Eric Kottmeier leads the organization from its North Vancouver headquarters at 828 Harbourside Drive. This diversified approach positions Waverunner to capture opportunities across emerging industries while maintaining flexibility in deal structures including recapitalizations and secondary limited partner interest investments.

Financial Health and Key Metrics Analysis

CHM.CN’s financial metrics reveal significant challenges typical of early-stage venture capital firms. The company reports a negative EPS of -C$0.01 with a PE ratio of -5.0, reflecting ongoing losses. Net income per share stands at -C$0.0595, while operating cash flow per share is -C$0.0044.

The current ratio of 0.097 indicates tight liquidity, though this is common for venture firms deploying capital into investments. Book value per share is -C$0.1422, suggesting negative shareholder equity. However, cash per share of C$0.0080 provides some operational flexibility. Track CHM.CN on Meyka for real-time updates on these metrics as the company executes its venture capital strategy.

Market Sentiment and Trading Activity

The 900% price surge reflects significant market sentiment shift following Waverunner’s rebranding announcement. This dramatic move suggests investor enthusiasm for the company’s pivot from its previous Chemistree Technology focus toward venture capital investing.

The five-day change of 400% and one-year change of 400% demonstrate sustained upward momentum beyond the recent spike. However, the three-year change of -9.09% and five-year decline of -80.39% show the stock’s historical struggles before this recent recovery. The stock’s movement from penny-stock territory to C$0.05 represents a meaningful revaluation, though investors should note the company’s negative profitability metrics and tight liquidity position require careful monitoring.

Final Thoughts

CHM.CN stock’s 900% surge to C$0.05 marks a significant turning point for Waverunner Capital Inc. following its venture capital rebranding. The company’s diversified investment approach across renewable energy, biotechnology, and growth-stage ventures positions it to benefit from emerging market opportunities. However, investors must recognize the financial challenges: negative earnings, tight liquidity, and a current ratio of 0.097 indicate operational constraints. The stock’s dramatic price movement reflects market optimism about the new strategic direction, but the company’s negative profitability metrics and modest market cap of C$37.2 million warrant cautious evaluation. Meyka AI…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.